PH12021550213A1 - Methods for treating neurodegenerative disorders - Google Patents

Methods for treating neurodegenerative disorders

Info

Publication number
PH12021550213A1
PH12021550213A1 PH12021550213A PH12021550213A PH12021550213A1 PH 12021550213 A1 PH12021550213 A1 PH 12021550213A1 PH 12021550213 A PH12021550213 A PH 12021550213A PH 12021550213 A PH12021550213 A PH 12021550213A PH 12021550213 A1 PH12021550213 A1 PH 12021550213A1
Authority
PH
Philippines
Prior art keywords
methods
neurodegenerative disorders
treating neurodegenerative
treating
disorders
Prior art date
Application number
PH12021550213A
Other languages
English (en)
Inventor
John Hey
Petr Kocis
Martin Tolar
Neil William Flanzraich
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of PH12021550213A1 publication Critical patent/PH12021550213A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PH12021550213A 2018-08-01 2021-01-28 Methods for treating neurodegenerative disorders PH12021550213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01
PCT/US2019/044023 WO2020028290A1 (en) 2018-08-01 2019-07-30 Methods for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
PH12021550213A1 true PH12021550213A1 (en) 2021-11-03

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550213A PH12021550213A1 (en) 2018-08-01 2021-01-28 Methods for treating neurodegenerative disorders

Country Status (27)

Country Link
US (2) US12083082B2 (cg-RX-API-DMAC7.html)
EP (1) EP3829563B1 (cg-RX-API-DMAC7.html)
JP (1) JP7573512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716959B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867485A (cg-RX-API-DMAC7.html)
AU (1) AU2019315853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001739A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000269A1 (cg-RX-API-DMAC7.html)
DK (1) DK3829563T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190406A1 (cg-RX-API-DMAC7.html)
ES (1) ES3011716T3 (cg-RX-API-DMAC7.html)
FI (1) FI3829563T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250206T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070101T2 (cg-RX-API-DMAC7.html)
IL (1) IL280424B2 (cg-RX-API-DMAC7.html)
LT (1) LT3829563T (cg-RX-API-DMAC7.html)
MX (1) MX2021001287A (cg-RX-API-DMAC7.html)
MY (1) MY206530A (cg-RX-API-DMAC7.html)
PH (1) PH12021550213A1 (cg-RX-API-DMAC7.html)
PL (1) PL3829563T3 (cg-RX-API-DMAC7.html)
PT (1) PT3829563T (cg-RX-API-DMAC7.html)
RS (1) RS66516B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100767XA (cg-RX-API-DMAC7.html)
SI (1) SI3829563T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500080T1 (cg-RX-API-DMAC7.html)
UA (1) UA130011C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020028290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
PH12021553196A1 (en) * 2019-06-17 2022-11-07 Alzheon Inc Methods for treating neurodegenerative disorders
AU2022405026A1 (en) * 2021-12-09 2024-06-20 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
SI2089417T1 (sl) * 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2014121083A1 (en) * 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
ES2960625T3 (es) * 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.

Also Published As

Publication number Publication date
EP3829563A1 (en) 2021-06-09
US20250213507A1 (en) 2025-07-03
ES3011716T3 (en) 2025-04-08
EA202190406A1 (ru) 2021-10-15
BR112021001739A2 (pt) 2021-04-27
HUE070101T2 (hu) 2025-05-28
AU2019315853A1 (en) 2021-03-18
KR102716959B1 (ko) 2024-10-11
SMT202500080T1 (it) 2025-03-12
US12083082B2 (en) 2024-09-10
RS66516B1 (sr) 2025-03-31
LT3829563T (lt) 2025-02-25
CL2021000269A1 (es) 2021-06-18
PL3829563T3 (pl) 2025-04-07
IL280424B2 (en) 2025-01-01
SI3829563T1 (sl) 2025-05-30
MY206530A (en) 2024-12-19
SG11202100767XA (en) 2021-02-25
AU2019315853B2 (en) 2025-05-01
JP2021533128A (ja) 2021-12-02
MX2021001287A (es) 2021-07-15
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
CN112867485A (zh) 2021-05-28
IL280424B1 (en) 2024-09-01
KR20210039415A (ko) 2021-04-09
US20210315847A1 (en) 2021-10-14
FI3829563T3 (fi) 2025-02-17
CA3108150A1 (en) 2020-02-06
WO2020028290A1 (en) 2020-02-06
PT3829563T (pt) 2025-02-18
HRP20250206T1 (hr) 2025-04-11
DK3829563T3 (en) 2025-02-24
JP7573512B2 (ja) 2024-10-25
IL280424A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
ZA201900519B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer&#39;s disease
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
TN2018000005A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MX2024005935A (es) Metodos para aumentar la exposicion al plasma de sepiapterina.
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12022551228A1 (en) Trem2 antibodies and uses thereof
JOP20200041A1 (ar) تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
IL278813A (en) Gene therapy for Alzheimer&#39;s disease
MX378940B (es) Trastornos neurodegenerativos.
MX378739B (es) Compuestos de 2-oxindol.
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
MY184878A (en) Compositions and methods for treating neurodegenerative diseases
MY206530A (en) Methods for treating neurodegenerative disorders
IL280326A (en) Small RNA contracts for Alzheimer&#39;s disease
EA202190359A1 (ru) Способы лечения нейродегенеративных расстройств
ZA202006126B (en) Compounds for treating alzheimer&#39;s disease
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer&#39;s disease
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER&#39;S MORBUS
WO2015186144A3 (en) Method of inhibition of beta-secretase by using bis-o-demethylcurcumin for the prevention, management and treatment of neurodegenerative diseases
AU2018903530A0 (en) Treatment for Alzheimer&#39;s Disease
HK40041162A (en) Compounds for treating alzheimer&#39;s disease
TN2016000549A1 (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer&#39;s